Efficacy of Early Ivermectin Administration in Acute Chikungunya Virus Infection: A Multicenter, Open-Label, Randomized Controlled Trial (2026)

Peer-Reviewed Study · Chusri S, Surasombatpattana S, Siripaitoon P, Kositpantawong N, Kanchanasuwan S, et al. · 2026

Chusri S et al., 2026: Open-label randomized trial in 127 Thai adults with acute chikungunya: three days of ivermectin 400 micrograms/kg within 72 hours of symptom onset cut persistent joint pain at one month from 30% to 6.6% and shortened fever and joint-pain duration.

Ivermectin was associated with a 92% reduction in the odds of persistent joint pain at 1 month (6.6% vs 30%; adjusted odds ratio (aOR) 0.08, 95% CI 0.03, 0.21; p < 0.0001).

Chusri S et al., 2026: Open-label randomized trial in 127 Thai adults with acute chikungunya: three days of ivermectin 400 micrograms/kg within 72 hours of symptom onset cut persistent joint pain at one month from 30% to 6.6% and shortened fever and joint-pain duration. Multicentre, open-label, randomized controlled trial, Thailand; 127 randomized, 120 in the complete-case primary analysis (60 per arm); oral ivermectin 400 micrograms/kg/day for 3 days plus standard of care vs standard of care alone; co-primary outcomes time to joint pain clearance (median 3.5 vs 12.0 days; aHR 3.65, 95% CI 2.28-5.84) and persistent joint pain at 1 month (6.6% vs 30%; aOR 0.08, 0.03-0.21); fever clearance 2.0 vs 5.0 days; faster viral clearance by day 7. No funding or conflict statement is carried in the PubMed record. Important caveat recorded as published: the trial registration (NCT06259383) was retrospective, posted 20 February 2024, which the authors disclose in the abstract. No blinding , an open-label design, which matters for a subjective endpoint like joint pain. Study type: randomized trial.